Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis

Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis

Introduction. PTK/ZK is a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor receptor, colony-stimulating factor 1 receptor, and cytokine stem cell factor receptor. Cetuximab is a monoclonal antibody against epidermal growth fact...

Full description

Bibliographic Details
Main Authors: Marlies H.G. Langenberg, Petronella O. Witteveen, Nienke A.G. Lankheet, Jeanine M.L. Roodhart, Hilde Rosing, Ingeborg J.G.M. van den Heuvel, Jos H. Beijnen, Emile E. Voest
Format: Article
Language:English
Published: Elsevier 2010-02-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558610800995

Internet

http://www.sciencedirect.com/science/article/pii/S1476558610800995

Similar Items